Clinical Lymphoma Myeloma & Leukemia

Papers
(The H4-Index of Clinical Lymphoma Myeloma & Leukemia is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
OA-27 Para-Medullary (PMD) and Extra-Medullary (EMD) Myeloma Demonstrate Increased Copy Number Aberration, Mutational Burden, Structural Variants and Genomic Complexity Compared to Marrow-Based Myelom59
P-012 Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma46
P-113 An Artificial Intelligence-Based 3D-Segmentation Assessment of Sarcopenia Utilizing Whole-Body Computed Tomography in Patients With Multiple Myeloma36
P-068 Developing Novel DKK1-A2 CAR-T Cell Therapy for Myeloma and Other Hematologic Malignancies36
P-112 Fall Risk Assessment and Fall Prevention in Patients With Multiple Myeloma: First Results of the MYFALL-Trial34
P-154 Multidisciplinary, Patient-Centric Bone Disease Management in Multiple Myeloma – a Single-Centre Experience32
P-202 Risk Factors Predicting Early Relapse for Newly Diagnosed Multiple Myeloma Patients Treated with Front-Line VRD Regimen30
P-186 Identifying a New Risk-Stratification Strategy by Including Single-Cell Biomarkers in Multiple Myeloma30
P-314 Daratumumab for Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin G Deposits and Severe Chronic Kidney Disease28
P-330 Stem Cell Mobilization Strategy With Pegilgrastim for Stem Cell Transplantation for Multiple Myeloma: A Direct Cost Comparison28
P-232 Comprehensive Genomic Sequencing Predicts Sub-Optimal Response to Bispecific Antibodies (BsAb) and Chimeric Antigen Receptor T Cells (CAR-T) in Multiple Myeloma (MM)27
P-309 Diagnostic Challenges in Systemic Amyloidosis: Exploring the Impact of Mass Spectrometry in a Middle-Income Country Cohort27
P-342 Impact of Achieving <VGPR With Dara-RVD Induction Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients25
MM-508 Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update24
Poster: CT-195 Predictive Value of ST2, REG3a, and MAGIC Algorithm in Haploidentical Transplantation With Post-Transplant Cyclophosphamide Outcomes22
Poster: CT-329 CD19-Directed Chimeric Antigen Receptor T Cell Therapy in Waldenström Macroglobulinemia: Initial Experience in Two Clinical Trials22
Poster: CT-227 Dual CAR-Engineered NK92 Cells: An Off-the-Shelf Cell Therapy for Cancer21
Poster: AML-295: Clinical Characteristics and Outcome of Acute Leukemia in Lebanese Patients: A Retrospective Observational Analysis21
POSTER: MDS-156 Pyrimethamine Shows Synergy and Efficacy in Combination With Venetoclax in Preclinical Models of Therapy Resistant MDS/AML20
AML-156 Early Deaths in Patients With Newly Diagnosed Acute Promyelocytic Leukemia: A Single-Center Retrospective Study From a General Hospital20
0.20744609832764